Immunic appoints jason tardio as chief operating officer and president

– former novartis and biogen executive brings extensive multiple sclerosis drug commercialization experience to immunic – – werner gladdines, current vice president, program management & clinical development operations, promoted to chief development officer – new york , july 9, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, jason tardio, will be joining the company as chief operating officer and president, effective july 12, 2024. in the newly created role, mr.
IMUX Ratings Summary
IMUX Quant Ranking